Coagulation studies: achieving the right mix in a large laboratory network. Pathology. 2019 Dec;51(7):718-722. \[[PubMed: 31668405](https://pubmed.ncbi.nlm.nih.gov/31668405)\] 2. Dorgalaleh A, Favaloro EJ, Bahraini M, Rad F. Standardization of Prothrombin Time/International Normalized Ratio (PT/INR). Int J Lab Hematol. 2021 Feb;43(1):21-28. \[[PubMed: 32979036](https://pubmed.ncbi.nlm.nih.gov/32979036)\] 3. Feinbloom D, Freed JA, Carbo A, Jung Y, Adra M, Herzig SJ. Incidence and risk factors for PTT prolongation in patients receiving low-dose unfractionated heparin thromboprophylaxis. J Thromb Thrombolysis. 2021 Jul;52(1):331-337. \[[PubMed: 33006065](https://pubmed.ncbi.nlm.nih.gov/33006065)\] 4. Toulon P, Smahi M, De Pooter N. APTT therapeutic range for monitoring unfractionated heparin therapy. Significant impact of the anti-Xa reagent used for correlation. J Thromb Haemost. 2021 Aug;19(8):2002-2006. \[[PubMed: 33555096](https://pubmed.ncbi.nlm.nih.gov/33555096)\] 5. Weitz JI, Fredenburgh JC, Eikelboom JW. A Test in Context: D-Dimer. J Am Coll Cardiol. 2017 Nov 07;70(19):2411-2420. \[[PubMed: 29096812](https://pubmed.ncbi.nlm.nih.gov/29096812)\] 6. Ignjatovic V. Activated partial thromboplastin time. Methods Mol Biol. 2013;992:111-20. \[[PubMed: 23546708](https://pubmed.ncbi.nlm.nih.gov/23546708)\] 7. Chornenki NLJ, Fralick M, Sholzberg M. International normalized ratio and activated partial thromboplastin time testing. CMAJ. 2022 Aug 29;194(33):E1135. \[[PMC free article: PMC9435534](/pmc/articles/PMC9435534/)\] \[[PubMed: 36302103](https://pubmed.ncbi.nlm.nih.gov/36302103)\] 8. Barcellona D, Fenu L, Marongiu F. Point-of-care testing INR: an overview. Clin Chem Lab Med. 2017 May 01;55(6):800-805. \[[PubMed: 27754958](https://pubmed.ncbi.nlm.nih.gov/27754958)\] 9. Robert-Ebadi H, Righini M. D-dimer: Well beyond diagnosis! J Med Vasc. 2020 Sep;45(5):239-240. \[[PMC free article: PMC7343641](/pmc/articles/PMC7343641/)\] \[[PubMed: 32862979](https://pubmed.ncbi.nlm.nih.gov/32862979)\] 10. Sikes L, Charles K, Antigua A, Patel R, Imboywa S, Cherian P. Anti-Factor Xa Level Monitoring for Enoxaparin Prophylaxis and Treatment in High-Risk Patient Groups. HCA Healthc J Med. 2023;4(2):105-109. \[[PMC free article: PMC10324872](/pmc/articles/PMC10324872/)\] \[[PubMed: 37424985](https://pubmed.ncbi.nlm.nih.gov/37424985)\] **Disclosure:** Syed Rafay Zaidi declares no relevant financial relationships with ineligible companies. **Disclosure:** Preeti Rout declares no relevant financial relationships with ineligible companies.